Skip to main content
. Author manuscript; available in PMC: 2019 Mar 13.
Published in final edited form as: Pharmacogenomics J. 2018 Sep 12;19(3):305–314. doi: 10.1038/s41397-018-0043-3

Figure 6. 341 patients had at least one methemoglobin measurement in their medical record, 21 of whom had deficient G6PD activity.

Figure 6.

27 patients developed methemoglobinemia at some point during therapy (12 males and 15 females). All 3 patients with deficient G6PD activity developed elevated methemoglobinemia (>3%) after rasburicase administration, and all had a class I-III allele. Of the 24 patients with normal G6PD activity who developed methemoglobinemia at any time during therapy, 3 experienced methemoglobinemia after rasburicase administration. The one male was hemizygous for a Class I-III allele (he had received a transfusion prior to the activity assay**). One female was heterozygous for a Class I-III allele, and one female did not have a Class I-III allele (but was interrogated by the Exomechip array only). Of the other 21 patients with normal G6PD activity who experienced methemoglobinemia, 10 patients received another medication associated with methemoglobinemia.